RNA Processing in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@mori2013]
RNA Processing in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@mori2013]
RNA Processing in Neurodegeneration refers to the dysregulation of post-transcriptional RNA metabolism—including splicing, editing, transport, and stability—that contributes to the pathogenesis of neurodegenerative diseases. The nervous system is particularly dependent on precise RNA processing due to the complex spatial and temporal regulation required for neuronal function, synaptic plasticity, and long-distance axonal transport. Emerging evidence demonstrates that mutations in RNA-binding proteins and defects in RNA processing pathways are central mechanisms in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease, Parkinson's disease, and Huntington's disease. [@zu2013]
--- [@kim2013]
Neurons are uniquely dependent on sophisticated RNA processing mechanisms due to their polarized architecture, requiring precise mRNA localization to distant synapses and axons. The central dogma of molecular biology describes the flow of genetic information from DNA to RNA to protein, but post-transcriptional regulation adds critical layers of complexity. RNA processing encompasses multiple co-transcriptional and post-transcriptional modifications, including alternative splicing, RNA editing, 5' capping, 3' polyadenylation, nuclear export, subcellular localization, translation control, and degradation. [@ishigaki2012]
In neurodegenerative diseases, these carefully orchestrated processes become disrupted through multiple mechanisms: pathogenic mutations in RNA-binding proteins, toxic RNA foci formation, altered expression of processing factors, and downstream effects of disease proteins. Understanding these dysregulations provides not only mechanistic insights but also identifies potential therapeutic targets. [@ling2013]
--- [@batra2010]
Alternative splicing allows a single gene to generate multiple protein isoforms, dramatically expanding proteomic diversity. In the nervous system, tissue-specific and activity-dependent splicing patterns are essential for neuronal development, neurotransmitter receptor composition, and synaptic plasticity. Key splicing regulators include the HNRNPs (heterogeneous nuclear ribonucleoproteins) family, SR (serine/arginine) proteins, and neuron-specific splicing factors like Nova-1 and RBFOX proteins [Licatalosi et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18629153/). [@zhou2014]
Adenosine-to-inosine (A-to-I) editing, mediated by ADAR (adenosine deaminase acting on RNA) enzymes, recodes genomic information post-transcriptionally. This modification is particularly prevalent in the brain, where it regulates neurotransmitter receptor function—including glutamate receptor subunits—and ion channel properties [Hogg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21889136/). [@haeusler2014]
Neurons utilize RNA transport granules to deliver mRNAs to specific subcellular domains. Zipcode-binding proteins (ZBPs) and fragile X mental retardation protein (FMRP) regulate dendritic mRNA localization and translation, critical for synaptic plasticity and response to neuronal activity [King et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24315917/). [@cooper2012]
--- [@berson2012]
[TAR DNA-binding protein 43](/proteins/tdp-43) (TDP-43) is a 414-amino acid nuclear protein encoded by the TARDBP gene. Originally identified as a transcriptional repressor binding to the TAR element of HIV-1, TDP-43 is now recognized as a master regulator of RNA metabolism [Ou et al. (1995)](https://pubmed.ncbi.nlm.nih.gov/7642964/). Pathological TDP-43 aggregates characterize most cases of ALS and approximately 50% of FTD, termed FTLD-TDP [Neumann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17023659/). [@sclip2016]
TDP-43 regulates thousands of RNAs, including those involved in RNA splicing, stability, transport, and translation. Disease-causing mutations in TARDBP demonstrate that loss of TDP-43 function or gain of toxicity disrupts these processes [Buratti et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15687273/). TDP-43 aggregation leads to its depletion from the nucleus and loss of its splicing regulatory function, particularly affecting critical neuronal transcripts [Amador-Ortiz et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18003963/). [@love2015]
[Fused in sarcoma](/proteins/fus) (FUS) is another RNA-binding protein with prion-like properties that forms pathological inclusions in ALS and FTD. Similar to TDP-43, FUS regulates multiple aspects of RNA processing, including splicing, transcription, and RNA transport [Lagier-Tourenne et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22441211/). Mutations in FUS cause familial ALS through toxic gain-of-function mechanisms, with FUS-positive inclusions observed in a subset of ALS/FTD cases [Mackenzie et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21666688/). [@stilling2014]
The GGGGCC hexanucleotide repeat expansion in the C9orf72 gene represents the most common genetic cause of familial ALS and FTD [DeJesus-Hernandez et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21944778/). This expansion produces toxic RNA foci that sequester essential RNA-binding proteins, including [TDP-43](/proteins/tdp-43), [FUS](/proteins/fus), and HNRNPs, disrupting normal RNA processing [Mori et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23583677/). Additionally, translation of the expanded repeat produces dipeptide repeat (DPR) proteins that may further disrupt nucleocytoplasmic transport and RNA granule dynamics [Zu et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24210922/). [@lambert2013]
The HNRNPs family comprises abundant nuclear RNA-binding proteins with diverse functions. [HNRNPA1](/proteins/hnrnp-a1) and [HNRNPA2B1](/proteins/hnrnp-a2b1) mutations cause familial inclusion body myopathy and accelerate ALS pathogenesis [Kim et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23439564/). [HNRNPM](/proteins/hnrnpm) and [SFPQ](/proteins/sfpq) have also been implicated in neuronal RNA processing dysregulation [Ishigaki et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22573262/). [@bosco2010]
--- [@jensen2013]
ALS and FTD exist along a clinical and pathological continuum, with shared genetic, molecular, and neuropathological features. RNA processing dysregulation represents a central pathogenic mechanism [Ling et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23624639/). [@kim2011]
TDP-43 pathology is observed in approximately 95% of ALS cases and 50% of FTD cases. Pathological TDP-43 is hyperphosphorylated, ubiquitinated, and forms cytoplasmic aggregates, leading to nuclear depletion and loss of function [Neumann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17023659/). Transcriptomic analyses of ALS patient tissues and model systems reveal widespread splicing abnormalities, including cryptic splicing events that introduce premature termination codons [Batra et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20074032/). [@martin2014]
FUS pathology occurs in approximately 5-10% of ALS cases, particularly in cases with early onset and rapid progression. FUS-positive inclusions also characterize certain FTD subtypes [Mackenzie et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21666688/). FUS regulates splicing of its own pre-mRNA and numerous neuronal transcripts, with disease mutations disrupting these regulatory functions [Zhou et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576652/). [@raman2015]
C9orf72 expansions cause both ALS and FTD through toxic RNA foci formation and DPR protein production. RNA foci sequester RNA-binding proteins, leading to widespread processing dysregulation [Haeusler et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25031428/). Patient-derived neurons exhibit specific splicing changes in genes involved in neuronal development and function [Cooper et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22995833/). [@liu2013]
[Alzheimer's disease](/diseases/alzheimers-disease) (AD), the most common cause of dementia, involves progressive memory loss and cognitive decline. While traditionally considered a proteinopathy driven by amyloid-beta (Aβ) and tau pathology, increasing evidence links AD to RNA processing abnormalities [Berson et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22879520/). [@takahashi2010]
The tau protein, which forms neurofibrillary tangles in AD, influences RNA splicing through interactions with splicing regulators. Tau pathology disrupts the nuclear membrane and may sequester splicing factors [Sclip et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27596618/). AD brain samples show altered expression and localization of HNRNPs and splicing regulators [Love et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26186141/). [@lin2016]
RNA sequencing studies in AD brain reveal widespread transcriptomic changes, including alterations in splicing patterns of genes involved in synaptic function, mitochondrial dynamics, and inflammation [Stilling et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25374103/). AD-associated genetic risk factors include variants in genes encoding RNA-binding proteins, suggesting a functional role in disease pathogenesis [Lambert et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23528757/). [@polymenidou2012]
[Parkinson's disease](/diseases/parkinsons-disease) (PD) is characterized by dopaminergic neuron loss and cytoplasmic Lewy bodies containing α-synuclein. RNA processing abnormalities contribute to PD pathogenesis through multiple mechanisms [Bosco et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20629169/). [@gendron2014]
α-Synuclein, the major component of Lewy bodies, binds RNA and may directly perturb RNA processing [Jensen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23801762/). Expression of mutant α-synuclein in cellular models disrupts splicing patterns and leads to mislocalization of splicing factors [Kim et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21364737/). [@hasegawa2008]
PD-associated genes, including LRRK2, PINK1, and PARKIN, influence RNA processing pathways. LRRK2 kinase activity regulates translation and may phosphorylate RNA-binding proteins [Martin et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24812089/). Furthermore, mitochondrial dysfunction in PD affects nuclear RNA processing through retrograde signaling pathways [Raman et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26203055/).
Huntington's disease (HD) is caused by CAG repeat expansion in the HTT gene, producing mutant huntingtin protein with an expanded polyglutamine tract. RNA processing dysregulation is a major pathogenic mechanism in HD [Liu et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24242361/).
Mutant huntingtin interacts with RNA-binding proteins, including [TDP-43](/proteins/tdp-43), [FUS](/proteins/fus), and various HNRNPs, altering their function and localization [Takahashi et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20220192/). Transcriptomic analyses of HD patient brains and model systems reveal widespread splicing abnormalities, including disrupted regulation of alternative splicing in neuronal genes [Lin et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27105056/).
Pathological protein aggregates in neurodegenerative diseases sequester essential RNA-binding proteins, depleting them from their normal nuclear or cytoplasmic locations. [TDP-43](/proteins/tdp-43) aggregates in ALS/FTD, [FUS](/proteins/fus) aggregates in FUS-ALS, and α-synuclein aggregates in PD all capture RNA-binding proteins, disrupting their normal functions [Polymenidou et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22815599/).
Expanded nucleotide repeats in non-coding regions form toxic RNA foci that sequester RNA-binding proteins. [C9orf72](genes/c9orf72) ALS/FTD represents the prototypical example, with hundreds to thousands of GGGGCC repeats producing RNA foci throughout the nervous system [Gendron et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24748765/).
Neurodegenerative diseases alter the expression and subcellular localization of RNA-binding proteins. TDP-43 mislocalizes from the nucleus to cytoplasmic aggregates in ALS/FTD, causing loss of its nuclear splicing regulatory function [Buratti et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16321972/).
Phosphorylation, ubiquitination, and other post-translational modifications regulate RNA-binding protein function. Pathological modifications, such as TDP-43 hyperphosphorylation in ALS/FTD, alter its aggregation properties and interactions with RNA targets [Hasegawa et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18234846/).
Pharmacological intervention in RNA processing pathways has emerged as a promising therapeutic strategy. Several small molecules have been developed to target key enzymes in RNA metabolism.
Splice-modulating compounds: Several compounds have been identified that can modulate alternative splicing. SMN-inducing compounds like SMA-1 and RG3039 have shown promise in increasing SMN protein levels in spinal muscular atrophy models PMID: 23474456. Similarly, splice-switching oligonucleotides combined with small molecules have shown synergistic effects in restoring proper splicing patterns.
RNA-binding protein modulators: Compounds targeting RNA-binding proteins have been developed. Small molecules that modulate TDP-43 aggregation or alter its nuclear-cytoplasmic shuttling are under investigation for ALS and FTD PMID: 24512688.
Kinase inhibitors: Several kinases involved in RNA processing phosphorylation events have been targeted. CDK9 inhibitors and topoisomerase inhibitors have shown effects on transcriptional regulation and RNA processing in models of neurodegeneration PMID: 23867245.
ASOs represent a powerful approach to directly modulate RNA processing. These single-stranded oligonucleotides can be designed to induce exon skipping or inclusion, target toxic RNA species for degradation, block translation of disease-causing proteins, or restore normal splicing patterns.
Clinical applications: Several ASO therapies have reached clinical trials:
Viral vector-mediated gene delivery offers potential for long-term therapeutic benefit:
AAV-based therapies: Delivery of RNA-binding proteins or splicing factors, expression of engineered RNA targeting constructs, and knockdown of toxic RNA species using RNAi constructs.
CRISPR-Cas approaches: Allele-specific editing of disease-causing mutations, correction of splicing defects, and modulation of expression of RNA-binding proteins.
Stress granules and other RNA granules are pathologically altered in neurodegeneration. Compounds that prevent aberrant granule assembly or promote disassembly, agents that modulate liquid-liquid phase separation, and strategies to enhance autophagy and proteasome-mediated clearance of pathological granules are under investigation.
RNA processing dysregulation represents a fundamental mechanism in neurodegenerative diseases. From [TDP-43](/proteins/tdp-43) pathology in ALS/FTD to altered splicing patterns in [Alzheimer's disease](/diseases/alzheimers-disease), disrupted post-transcriptional regulation contributes to neuronal dysfunction and death. The interconnected nature of RNA processing pathways—whereby mutations or stress affecting one RNA-binding protein cascade into broader transcriptomic disruption—highlights the vulnerability of neuronal RNA metabolism.
Future research should focus on characterizing disease-specific RNA processing alterations, developing biomarkers based on RNA processing endpoints, and advancing therapeutic strategies targeting these dysregulated pathways. As our understanding deepens, RNA processing-targeted therapies may offer meaningful benefits for patients with these devastating disorders.